Advocacy intelligence hub — real-time data for patient organizations
Ohio State University — PHASE1, PHASE2
Mayo Clinic — PHASE1
Precigen, Inc — PHASE4
Massachusetts General Hospital — NA
National Cancer Institute (NCI) — PHASE2
Imagine Institute
Precigen, Inc — PHASE1, PHASE2
Massachusetts General Hospital — PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Papzimeos
Precigen, Inc.
Papzimeos
(zopapogene imadenovec-drba)Orphan drugPrecigen, Inc.
12.1 Mechanism of Action PAPZIMEOS is a non-replicating adenoviral vector-based immunotherapy designed to express a fusion antigen of selected regions...
David G Lott, MD
Mayo Clinic
Bettie M Steinberg, PhD
Long Island Jewish Medical Center
Steven M Zeitels, MD, MD
Massachusetts General Hospital
📍 BOSTON, MA
Amy Lankford, PhD, PT
Precigen, Inc
📍 MANSFIELD, TX
Martin Formanek, MD
University Hospital Ostrava
Scott M Norberg, D.O., D.O
National Cancer Institute (NCI)
📍 PHILADELPHIA, PA